Literature DB >> 29307588

Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice.

Agnès Jamin1, Laureline Berthelot1, Anne Couderc2, Jonathan M Chemouny3, Erwan Boedec1, Laurène Dehoux2, Lilia Abbad1, Claire Dossier2, Eric Daugas3, Renato C Monteiro1, Georges Deschênes4.   

Abstract

Idiopathic steroid sensitive nephrotic syndrome (INS), the most frequent childhood nephropathy, is thought to be mediated by a circulating soluble factor that reversibly affects the renal protein sieving. The efficiency of rituximab therapy recently highlighted the involvement of B cells. Here we studied the involvement of a specific immunoglobulin G (IgG) in the disease. After plasma fractionation by size exclusion chromatography, a detachment of cultured podocyte was observed with one IgG-containing fraction from 47% patients in relapse, 9% of patients in remission and 0% of controls. Podocyte protein lysates were immunoprecipitated by IgG from those plasma fractions identifying a list of 41 podocyte proteins after proteomic analysis. Five podocyte targets were selected on statistical and biological criteria. Specific antibodies were tested and only anti-Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) IgG led to podocyte detachment. UCHL1 was mainly found inside the podocyte but also weakly expressed on podocyte cell surface. Incubation of either anti-UCHL1 IgG or plasma fractions with recombinant UCHL1 prevented podocyte detachment. Plasma levels of anti-UCHL1 IgG were significantly increased in relapsing INS patients compared to patients in remission and controls. Proteinuria correlated with anti-UCHL1 IgG level at various stages of the disease. Purified patient anti-UCHL1 antibodies induced proteinuria and podocyte foot effacement in mice. Altogether, these results identified UCHL1 as a target podocyte protein of autoantibodies in a set of relapsing patients and support a causative role of anti-UCHL1 autoantibodies in the development of INS.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Foot process effacement; Immunoglobulin; Pediatric nephrology; Proteinuria

Mesh:

Substances:

Year:  2018        PMID: 29307588     DOI: 10.1016/j.jaut.2017.12.014

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  16 in total

1.  How to improve response to rituximab treatment in children with steroid-dependent nephrotic syndrome: answer to Drs. Fujinaga and Nishino.

Authors:  Julien Hogan; Georges Deschenes
Journal:  Pediatr Nephrol       Date:  2018-11-07       Impact factor: 3.714

2.  B cell phenotype in pediatric idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Rita Carsetti; Simona Cascioli; Jessica Serafinelli; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2018-09-28       Impact factor: 3.714

3.  Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.

Authors:  Pietro Ravani; Manuela Colucci; Maurizio Bruschi; Marina Vivarelli; Michela Cioni; Armando DiDonato; Paolo Cravedi; Francesca Lugani; Francesca Antonini; Marco Prunotto; Francesco Emma; Andrea Angeletti; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2021-09-20       Impact factor: 14.978

Review 4.  The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature.

Authors:  Konstantina Kitsou; Varvara Askiti; Andromachi Mitsioni; Vana Spoulou
Journal:  Eur J Pediatr       Date:  2022-01-31       Impact factor: 3.860

5.  Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study.

Authors:  Marina Vivarelli; Manuela Colucci; Antonio Gargiulo; Chiara Bettini; Anna Lo Russo; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2021-08-05       Impact factor: 3.714

6.  Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series.

Authors:  Hamza Naciri Bennani; Thomas Jouve; Johan Noble; Lionel Rostaing; Paolo Malvezzi; Rachel Tetaz
Journal:  Case Rep Nephrol       Date:  2019-10-09

Review 7.  CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.

Authors:  Yoong Mond Teh; Soo Kun Lim; Norhana Jusoh; Kahar Osman; Siti Aisyah Mualif
Journal:  Biomed Res Int       Date:  2021-01-06       Impact factor: 3.411

8.  Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys.

Authors:  Léa Moret; Alexandre Ganea; Myriam Dao; Aurélie Hummel; Bertrand Knebelman; Jean François Subra; Johan Noble; Christophe Mariat; Noémie Jourde-Chiche; Fatouma Toure; Cyril Garrouste; Charlotte Laurent; Lacraz Adeline; Yahsou Delmas; Alexandre Cez; Olivier Fritz; Christiane Mousson; Lise Marie Pouteau; Olivier Moranne; Jean-Michel Halimi; Vincent Audard
Journal:  Kidney Int Rep       Date:  2021-05-06

Review 9.  Molecular Mechanisms of Proteinuria in Minimal Change Disease.

Authors:  Shrey Purohit; Federica Piani; Flor A Ordoñez; Carmen de Lucas-Collantes; Colin Bauer; Gabriel Cara-Fuentes
Journal:  Front Med (Lausanne)       Date:  2021-12-23

10.  Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.

Authors:  Diankun Liu; Zhanmei Zhou; Mengyi Wang; Sheng Nie; Jun Li; Bianxiang Hu; Wenjuan He; Guobao Wang; Jun Ai
Journal:  BMC Nephrol       Date:  2021-07-01       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.